Hepatic Effects of Gastric Bypass Surgery

Status Completed

Clinical Trial Summary

Liver disease in the morbidly obese is thought to occur due to the long-term presence of fat deposits in the liver, resulting in inflammation and scarring of the liver over time, which reduces liver function. However, many of these patients are unaware that their liver is damaged. There is currently no consensus regarding what the long-term effects of gastric bypass surgery are on pre-existing liver disease in morbidly obese patients. This study will determine the long-term effects on the liver after this type of surgical procedure.

Clinical Trial Description

Before or on the day of surgery liver function will be determined using the DDG-2001 Analyzer. This monitor is able to detect the concentration of a dye called indocyanine green dye (ICG) when present in the blood stream. A dose of 0.5 mg/kg of ICG will be injected into an IV in the arm. Over approximately fifteen minutes the DDG-2001 Analyzer will determine how quickly the liver removes the dye ICG from the blood stream. This value represents how well the liver is functioning. Blood samples are drawn before injection of ICG to measure liver function using standard liver function tests.

This same routine for injecting ICG and obtaining blood for routine liver function tests will happen one more time, after surgery, once the subject has lost a significant amount of the original weight (60% of excess weight). This amount of weight loss typically occurs between 12 to 18 months after gastric bypass surgery. This second ICG measurement will occur during an outpatient follow-up visit to CCF.

A biopsy will be taken from the liver during surgery. A second biopsy taken after the 60% weight loss will be compared to determine the effect of this surgery on the liver. ;

Study Design

Related Conditions & MeSH terms

Liver Diseases

Clinical Trial Details

NCT number	NCT00701376
Study type	Interventional
Source	The Cleveland Clinic
Contact
Status	Completed
Phase	N/A
Start date	June 2008
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05255042` - Tissue Models for Liver Disease
Completed	`NCT04473482` - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Recruiting	`NCT03773887` - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease	N/A
Recruiting	`NCT00345930` - DILIN - Prospective Study
Completed	`NCT00148031` - Improving Hepatitis C Treatment in Injection Drug Users	Phase 4
Terminated	`NCT00031135` - Total Parenteral Nutrition-Associated Liver Disease	Phase 2
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00222664` - Qidong Hepatitis B Intervention Study	Phase 4
Recruiting	`NCT06195917` - Robotic-assisted Percutaneous Transhepatic Puncture	N/A
Recruiting	`NCT04551742` - Social & Contextual Impact on Children Undergoing Liver Transplantation
Completed	`NCT04782050` - Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Recruiting	`NCT05499585` - Treating Pediatric NAFLD With Nutrition	N/A
Terminated	`NCT03396705` - Liver Regeneration
Completed	`NCT04341012` - Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Recruiting	`NCT05733832` - A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease	N/A